Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat

Biochemical and Biophysical Research Communications

Volumn 362, Issue 4, 2007, Pages 1007-1012

  Piteau, Shalea ^a   Olver, Amy ^a   Kim, Su Jin ^a   Winter, Kyle ^a   Pospisilik, John Andrew ^b   Lynn, Francis ^c   Manhart, Susanne ^d   Demuth, Hans Ulrich ^d   Speck, Madeleine ^a   Pederson, Raymond A ^a   McIntosh, Christopher H S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PROBIODRUG AG   (Germany)

Author keywords

Dipeptidyl peptidase IV; Gastric inhibitory polypeptide; Glucose dependent insulinotropic polypeptide; Hyperglycemia; Phlorizin; Receptor down regulation

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; ISOLEUCINE THIAZOLIDIDE; MESSENGER RNA; PHLORIZIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE SENSITIVITY; HYPERGLYCEMIA; IMMUNE RESPONSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS PERFUSION; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; ZUCKER RAT;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE; GASTRIC INHIBITORY POLYPEPTIDE; HYPERGLYCEMIA; INSULIN RESISTANCE; RATS; RATS, ZUCKER; RECEPTORS, GASTROINTESTINAL HORMONE; TREATMENT OUTCOME;

RATTUS; RODENTIA;

EID: 34548612361     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.08.115     Document Type: Article

References (32)

1. Drucker D.J. The biology of incretin hormones. Cell Metab. 3 (2006) 153-165
2. Fehmann H.-C., and Göke B. Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription. Peptides 16 (1995) 1149-1152
3. Fehmann H.-C., and Habener J.F. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 130 (1992) 159-166
4. Stoffers D.A., Kieffer T.J., Hussain M.A., Drucker D.J., Bonner-Weir S., Habener J.F., and Egan J.M. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 (2000) 741-748
5. Trümper A., Trümper K., Trüsheim H., Arnold R., Göke B., and Hörsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15 (2001) 1559-1570
6. Ehses J.A., Casilla V.R., Doty T., Pospisilik J.A., Winter K.D., Demuth H.U., Pederson R.A., and McIntosh C.H. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144 (2003) 4433-44345
7. Kim S.-J., Winter K., Nian C., Tsuneoka M., Koda Y., and McIntosh C.H.S. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 (Foxo1) and downregulation of bax expression. J. Biol. Chem. 280 (2005) 22297-22307
8. Nauck M., Stockmann F., Ebert R., and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
9. Vilsbøll T., Krarup T., Deacon C.F., Madsbad S., and Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
10. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91 (1993) 301-307
11. Elahi D., McAloon-Dyke M., Fukagawa N.K., Meneilly G.S., Sclater A.L., Minaker K.L., Habener J.F., and Andersen D.K. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. 51 (1994) 63-74
12. Vilsbøll T., Knop F.K., Krarup T., Johansen A., Madsbad S., Larsen S., Hansen T., Pedersen O., and Holst J.J. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J. Clin. Endocrinol. Metab. 88 (2003) 4897-4903
13. Holst J.J., Gromada J., and Nauck M.A. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40 (1997) 984-986
14. Lynn F.C., Pamir N., Ng E.H., McIntosh C.H.S., Kieffer T.J., and Pederson R.A. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50 (2001) 1004-1011
15. Lynn F.C., Thompson S.A., Pospisilik J.A., Ehses J.A., Hinke S.A., Pamir N., McIntosh C.H.S., and Pederson R.A. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J. 17 (2003) 91-93
16. Hinke S.A., Pauly R.P., Ehses J., Kerridge P., Demuth H.U., McIntosh C.H., and Pederson R.A. Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide. J. Endocrinol. 165 (2000) 281-291
17. Almind K., Ambye L., Urhammer S.A., Hansen T., Echwald S.M., Holst J.J., Gromada J., Thorens B., and Pedersen O. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41 (1998) 1194-1198
18. Kubota A., Yamada Y., Hayami T., Yasuda K., Someya Y., Ihara Y., Kagimoto S., Watanabe R., Taminato T., Tsuda K., and Seino Y. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 45 (1996) 1701-1705
19. Pospisilik J.A., Stafford S.G., Demuth H.-U., Brownsey R., Parkhouse W., Finegood D.T., McIntosh C.H.S., and Pederson R.A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51 (2002) 943-950
20. Pospisilik J.A., Stafford S.G., Demuth H.-U., McIntosh C.H.S., and Pederson R.A. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 51 (2002) 2677-2683
21. McIntosh C.H.S., Demuth H.-U., Kim S.J., Pospisilik J.A., and Pederson R.A. Applications of dipeptidyl peptidase inhibitors in diabetes mellitus. Int. J. Biochem. Cell. Biol. 38 (2006) 860-872
22. Demuth H.-U. Recent developments in inhibiting cysteine and serine proteases. J. Enzyme Inhib. 3 (1990) 249-278
23. Ehrenkranz J.R., Lewis N.G., Kahn C.R., and Roth J. Phlorizin: a review. Diabetes Metab. Res. Rev. 21 (2005) 31-38
24. Harmon J.S., Gleason C.E., Tanaka Y., Poitout V., and Robertson R.P. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triglyceride content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50 (2001) 2481-2486
25. Pederson R.A., and Brown J.C. The insulinotropic actions of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99 (1976) 780-785
26. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
27. Tseng C.C., Boylan M.O., Jarboe L.A., Usdin T.B., and Wolfe M.M. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am. J. Physiol. 270 (1996) E661-E666
28. Laybutt D.R., Sharma A., Sgroi D.C., Gaudet J., Bonner-Weir S., and Weir G.C. Genetic regulation of metabolic pathways in beta-cells disrupted by hyperglycemia. J. Biol. Chem. 277 (2002) 10912-10921
29. Xu G., Kaneto H., Laybutt D.R., Duvivier-Kali V.F., Trivedi N., Suzuma K., King G.L., Weir G.C., and Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56 (2007) 1551-1558
30. Lalloyer F., Vandewalle B., Percevault F., Torpier G., Kerr-Conte J., Oosterveer M., Paumelle R., Fruchart J.-C., Kuipers F., Patton F., Flévet C., and Staels B. Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 55 (2006) 1605-1613
31. Roduit R., Morin J., Masse F., Segall L., Roche E., Newgard C.B., Assimacopoulos-Jeannet F., and Prentki M. Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta cell. J. Biol. Chem. 275 (2000) 35799-35806
32. Zhou Y.T., Shimabukuro M., Wang M.Y., Lee Y., Higa M., Milburn J.L., Newgard C.B., and Unger R.H. Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc. Natl. Acad. Sci. USA 95 (1998) 8898-8903